img

Global Recombinant Plasma Proteins Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Recombinant Plasma Proteins Market Research Report 2024

For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-
According to MRAResearch’s new survey, global Recombinant Plasma Proteins market is projected to reach US$ 106.4 million in 2033, increasing from US$ 92 million in 2022, with the CAGR of 2.1% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Recombinant Plasma Proteins market research.
Key companies engaged in the Recombinant Plasma Proteins industry include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk, Bayer, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group and Pfizer, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Recombinant Plasma Proteins were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Recombinant Plasma Proteins market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Recombinant Plasma Proteins market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


CSL Limited
Shire (Takeda Pharmaceutical Company Limited)
Octapharma
Novo Nordisk
Bayer
Bioverativ Therapeutics, Inc. (Sanofi)
Aptevo Therapeutics
Pharming Group
Pfizer
Segment by Type
Chinese Hamster Ovary (CHO) Cell Line
Baby Hamster Kidney (BHK) Cell Line
Human Embryonic Kidney (HEK) Cell Line
Others

Segment by Application


Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Recombinant Plasma Proteins report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant Plasma Proteins Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Chinese Hamster Ovary (CHO) Cell Line
1.2.3 Baby Hamster Kidney (BHK) Cell Line
1.2.4 Human Embryonic Kidney (HEK) Cell Line
1.2.5 Others
1.3 Market by Application
1.3.1 Global Recombinant Plasma Proteins Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hemophilia A
1.3.3 Hemophilia B
1.3.4 Von Willebrand Disease
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant Plasma Proteins Market Perspective (2018-2033)
2.2 Recombinant Plasma Proteins Growth Trends by Region
2.2.1 Global Recombinant Plasma Proteins Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Recombinant Plasma Proteins Historic Market Size by Region (2018-2023)
2.2.3 Recombinant Plasma Proteins Forecasted Market Size by Region (2024-2033)
2.3 Recombinant Plasma Proteins Market Dynamics
2.3.1 Recombinant Plasma Proteins Industry Trends
2.3.2 Recombinant Plasma Proteins Market Drivers
2.3.3 Recombinant Plasma Proteins Market Challenges
2.3.4 Recombinant Plasma Proteins Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant Plasma Proteins Players by Revenue
3.1.1 Global Top Recombinant Plasma Proteins Players by Revenue (2018-2023)
3.1.2 Global Recombinant Plasma Proteins Revenue Market Share by Players (2018-2023)
3.2 Global Recombinant Plasma Proteins Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant Plasma Proteins Revenue
3.4 Global Recombinant Plasma Proteins Market Concentration Ratio
3.4.1 Global Recombinant Plasma Proteins Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant Plasma Proteins Revenue in 2022
3.5 Recombinant Plasma Proteins Key Players Head office and Area Served
3.6 Key Players Recombinant Plasma Proteins Product Solution and Service
3.7 Date of Enter into Recombinant Plasma Proteins Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant Plasma Proteins Breakdown Data by Type
4.1 Global Recombinant Plasma Proteins Historic Market Size by Type (2018-2023)
4.2 Global Recombinant Plasma Proteins Forecasted Market Size by Type (2024-2033)
5 Recombinant Plasma Proteins Breakdown Data by Application
5.1 Global Recombinant Plasma Proteins Historic Market Size by Application (2018-2023)
5.2 Global Recombinant Plasma Proteins Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Recombinant Plasma Proteins Market Size (2018-2033)
6.2 North America Recombinant Plasma Proteins Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Recombinant Plasma Proteins Market Size by Country (2018-2023)
6.4 North America Recombinant Plasma Proteins Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant Plasma Proteins Market Size (2018-2033)
7.2 Europe Recombinant Plasma Proteins Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Recombinant Plasma Proteins Market Size by Country (2018-2023)
7.4 Europe Recombinant Plasma Proteins Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant Plasma Proteins Market Size (2018-2033)
8.2 Asia-Pacific Recombinant Plasma Proteins Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2018-2023)
8.4 Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant Plasma Proteins Market Size (2018-2033)
9.2 Latin America Recombinant Plasma Proteins Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Recombinant Plasma Proteins Market Size by Country (2018-2023)
9.4 Latin America Recombinant Plasma Proteins Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant Plasma Proteins Market Size (2018-2033)
10.2 Middle East & Africa Recombinant Plasma Proteins Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2018-2023)
10.4 Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 CSL Limited
11.1.1 CSL Limited Company Detail
11.1.2 CSL Limited Business Overview
11.1.3 CSL Limited Recombinant Plasma Proteins Introduction
11.1.4 CSL Limited Revenue in Recombinant Plasma Proteins Business (2018-2023)
11.1.5 CSL Limited Recent Development
11.2 Shire (Takeda Pharmaceutical Company Limited)
11.2.1 Shire (Takeda Pharmaceutical Company Limited) Company Detail
11.2.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
11.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Introduction
11.2.4 Shire (Takeda Pharmaceutical Company Limited) Revenue in Recombinant Plasma Proteins Business (2018-2023)
11.2.5 Shire (Takeda Pharmaceutical Company Limited) Recent Development
11.3 Octapharma
11.3.1 Octapharma Company Detail
11.3.2 Octapharma Business Overview
11.3.3 Octapharma Recombinant Plasma Proteins Introduction
11.3.4 Octapharma Revenue in Recombinant Plasma Proteins Business (2018-2023)
11.3.5 Octapharma Recent Development
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Detail
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Recombinant Plasma Proteins Introduction
11.4.4 Novo Nordisk Revenue in Recombinant Plasma Proteins Business (2018-2023)
11.4.5 Novo Nordisk Recent Development
11.5 Bayer
11.5.1 Bayer Company Detail
11.5.2 Bayer Business Overview
11.5.3 Bayer Recombinant Plasma Proteins Introduction
11.5.4 Bayer Revenue in Recombinant Plasma Proteins Business (2018-2023)
11.5.5 Bayer Recent Development
11.6 Bioverativ Therapeutics, Inc. (Sanofi)
11.6.1 Bioverativ Therapeutics, Inc. (Sanofi) Company Detail
11.6.2 Bioverativ Therapeutics, Inc. (Sanofi) Business Overview
11.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Introduction
11.6.4 Bioverativ Therapeutics, Inc. (Sanofi) Revenue in Recombinant Plasma Proteins Business (2018-2023)
11.6.5 Bioverativ Therapeutics, Inc. (Sanofi) Recent Development
11.7 Aptevo Therapeutics
11.7.1 Aptevo Therapeutics Company Detail
11.7.2 Aptevo Therapeutics Business Overview
11.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Introduction
11.7.4 Aptevo Therapeutics Revenue in Recombinant Plasma Proteins Business (2018-2023)
11.7.5 Aptevo Therapeutics Recent Development
11.8 Pharming Group
11.8.1 Pharming Group Company Detail
11.8.2 Pharming Group Business Overview
11.8.3 Pharming Group Recombinant Plasma Proteins Introduction
11.8.4 Pharming Group Revenue in Recombinant Plasma Proteins Business (2018-2023)
11.8.5 Pharming Group Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Recombinant Plasma Proteins Introduction
11.9.4 Pfizer Revenue in Recombinant Plasma Proteins Business (2018-2023)
11.9.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Recombinant Plasma Proteins Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Chinese Hamster Ovary (CHO) Cell Line
Table 3. Key Players of Baby Hamster Kidney (BHK) Cell Line
Table 4. Key Players of Human Embryonic Kidney (HEK) Cell Line
Table 5. Key Players of Others
Table 6. Global Recombinant Plasma Proteins Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Recombinant Plasma Proteins Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Recombinant Plasma Proteins Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Recombinant Plasma Proteins Market Share by Region (2018-2023)
Table 10. Global Recombinant Plasma Proteins Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Recombinant Plasma Proteins Market Share by Region (2024-2033)
Table 12. Recombinant Plasma Proteins Market Trends
Table 13. Recombinant Plasma Proteins Market Drivers
Table 14. Recombinant Plasma Proteins Market Challenges
Table 15. Recombinant Plasma Proteins Market Restraints
Table 16. Global Recombinant Plasma Proteins Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Recombinant Plasma Proteins Market Share by Players (2018-2023)
Table 18. Global Top Recombinant Plasma Proteins Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Plasma Proteins as of 2022)
Table 19. Ranking of Global Top Recombinant Plasma Proteins Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Recombinant Plasma Proteins Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Recombinant Plasma Proteins Product Solution and Service
Table 23. Date of Enter into Recombinant Plasma Proteins Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Recombinant Plasma Proteins Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Recombinant Plasma Proteins Revenue Market Share by Type (2018-2023)
Table 27. Global Recombinant Plasma Proteins Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Recombinant Plasma Proteins Revenue Market Share by Type (2024-2033)
Table 29. Global Recombinant Plasma Proteins Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Recombinant Plasma Proteins Revenue Market Share by Application (2018-2023)
Table 31. Global Recombinant Plasma Proteins Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Recombinant Plasma Proteins Revenue Market Share by Application (2024-2033)
Table 33. North America Recombinant Plasma Proteins Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Recombinant Plasma Proteins Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Recombinant Plasma Proteins Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Recombinant Plasma Proteins Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Recombinant Plasma Proteins Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Recombinant Plasma Proteins Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Recombinant Plasma Proteins Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Recombinant Plasma Proteins Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Recombinant Plasma Proteins Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Recombinant Plasma Proteins Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Recombinant Plasma Proteins Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Recombinant Plasma Proteins Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Recombinant Plasma Proteins Market Size by Country (2024-2033) & (US$ Million)
Table 48. CSL Limited Company Detail
Table 49. CSL Limited Business Overview
Table 50. CSL Limited Recombinant Plasma Proteins Product
Table 51. CSL Limited Revenue in Recombinant Plasma Proteins Business (2018-2023) & (US$ Million)
Table 52. CSL Limited Recent Development
Table 53. Shire (Takeda Pharmaceutical Company Limited) Company Detail
Table 54. Shire (Takeda Pharmaceutical Company Limited) Business Overview
Table 55. Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Product
Table 56. Shire (Takeda Pharmaceutical Company Limited) Revenue in Recombinant Plasma Proteins Business (2018-2023) & (US$ Million)
Table 57. Shire (Takeda Pharmaceutical Company Limited) Recent Development
Table 58. Octapharma Company Detail
Table 59. Octapharma Business Overview
Table 60. Octapharma Recombinant Plasma Proteins Product
Table 61. Octapharma Revenue in Recombinant Plasma Proteins Business (2018-2023) & (US$ Million)
Table 62. Octapharma Recent Development
Table 63. Novo Nordisk Company Detail
Table 64. Novo Nordisk Business Overview
Table 65. Novo Nordisk Recombinant Plasma Proteins Product
Table 66. Novo Nordisk Revenue in Recombinant Plasma Proteins Business (2018-2023) & (US$ Million)
Table 67. Novo Nordisk Recent Development
Table 68. Bayer Company Detail
Table 69. Bayer Business Overview
Table 70. Bayer Recombinant Plasma Proteins Product
Table 71. Bayer Revenue in Recombinant Plasma Proteins Business (2018-2023) & (US$ Million)
Table 72. Bayer Recent Development
Table 73. Bioverativ Therapeutics, Inc. (Sanofi) Company Detail
Table 74. Bioverativ Therapeutics, Inc. (Sanofi) Business Overview
Table 75. Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Product
Table 76. Bioverativ Therapeutics, Inc. (Sanofi) Revenue in Recombinant Plasma Proteins Business (2018-2023) & (US$ Million)
Table 77. Bioverativ Therapeutics, Inc. (Sanofi) Recent Development
Table 78. Aptevo Therapeutics Company Detail
Table 79. Aptevo Therapeutics Business Overview
Table 80. Aptevo Therapeutics Recombinant Plasma Proteins Product
Table 81. Aptevo Therapeutics Revenue in Recombinant Plasma Proteins Business (2018-2023) & (US$ Million)
Table 82. Aptevo Therapeutics Recent Development
Table 83. Pharming Group Company Detail
Table 84. Pharming Group Business Overview
Table 85. Pharming Group Recombinant Plasma Proteins Product
Table 86. Pharming Group Revenue in Recombinant Plasma Proteins Business (2018-2023) & (US$ Million)
Table 87. Pharming Group Recent Development
Table 88. Pfizer Company Detail
Table 89. Pfizer Business Overview
Table 90. Pfizer Recombinant Plasma Proteins Product
Table 91. Pfizer Revenue in Recombinant Plasma Proteins Business (2018-2023) & (US$ Million)
Table 92. Pfizer Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recombinant Plasma Proteins Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Recombinant Plasma Proteins Market Share by Type: 2022 VS 2033
Figure 3. Chinese Hamster Ovary (CHO) Cell Line Features
Figure 4. Baby Hamster Kidney (BHK) Cell Line Features
Figure 5. Human Embryonic Kidney (HEK) Cell Line Features
Figure 6. Others Features
Figure 7. Global Recombinant Plasma Proteins Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Recombinant Plasma Proteins Market Share by Application: 2022 VS 2033
Figure 9. Hemophilia A Case Studies
Figure 10. Hemophilia B Case Studies
Figure 11. Von Willebrand Disease Case Studies
Figure 12. Others Case Studies
Figure 13. Recombinant Plasma Proteins Report Years Considered
Figure 14. Global Recombinant Plasma Proteins Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Recombinant Plasma Proteins Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Recombinant Plasma Proteins Market Share by Region: 2022 VS 2033
Figure 17. Global Recombinant Plasma Proteins Market Share by Players in 2022
Figure 18. Global Top Recombinant Plasma Proteins Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Plasma Proteins as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Recombinant Plasma Proteins Revenue in 2022
Figure 20. North America Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Recombinant Plasma Proteins Market Share by Country (2018-2033)
Figure 22. United States Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Recombinant Plasma Proteins Market Share by Country (2018-2033)
Figure 26. Germany Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Recombinant Plasma Proteins Market Share by Region (2018-2033)
Figure 34. China Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Recombinant Plasma Proteins Market Share by Country (2018-2033)
Figure 42. Mexico Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Recombinant Plasma Proteins Market Share by Country (2018-2033)
Figure 46. Turkey Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia Recombinant Plasma Proteins Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. CSL Limited Revenue Growth Rate in Recombinant Plasma Proteins Business (2018-2023)
Figure 49. Shire (Takeda Pharmaceutical Company Limited) Revenue Growth Rate in Recombinant Plasma Proteins Business (2018-2023)
Figure 50. Octapharma Revenue Growth Rate in Recombinant Plasma Proteins Business (2018-2023)
Figure 51. Novo Nordisk Revenue Growth Rate in Recombinant Plasma Proteins Business (2018-2023)
Figure 52. Bayer Revenue Growth Rate in Recombinant Plasma Proteins Business (2018-2023)
Figure 53. Bioverativ Therapeutics, Inc. (Sanofi) Revenue Growth Rate in Recombinant Plasma Proteins Business (2018-2023)
Figure 54. Aptevo Therapeutics Revenue Growth Rate in Recombinant Plasma Proteins Business (2018-2023)
Figure 55. Pharming Group Revenue Growth Rate in Recombinant Plasma Proteins Business (2018-2023)
Figure 56. Pfizer Revenue Growth Rate in Recombinant Plasma Proteins Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed